Effect of Clostridium butyricum on Gastrointestinal Infections

Abstract

Clostridium butyricum is a human commensal bacterium with beneficial effects including butyrate production, spore formation, increasing levels of beneficial bacteria, and inhibition of pathogenic bacteria. Owing to its preventive and ameliorative effects on gastrointestinal infections, C. butyricum MIYAIRI 588 (CBM 588) has been used as a probiotic in clinical and veterinary medicine for decades. This review summarizes the effects of C. butyricum, including CBM 588, on bacterial gastrointestinal infections. Further, the characteristics of the causative bacteria, examples of clinical and veterinary use, and mechanisms exploited in basic research are presented. C. butyricum is widely effective against Clostoridioides difficile, the causative pathogen of nosocomial infections; Helicobacter pylori, the causative pathogen of gastric cancer; and antibiotic-resistant Escherichia coli. Accordingly, its mechanism is gradually being elucidated. As C. butyricum is effective against gastrointestinal infections caused by antibiotics-induced dysbiosis, it can inhibit the transmission of antibiotic-resistant genes and maintain homeostasis of the gut microbiome. Altogether, C. butyricum is expected to be one of the antimicrobial-resistance (AMR) countermeasures for the One-health approach.

Clostridium butyricum and Its Culture Supernatant Alleviate the Escherichia coli-Induced Endometritis in Mice

“…Several studies have reported that the uterine infusion or vaginal infusion of probiotics is effective in the treatment of endometritis [ 29 , 30 , 31 ]. C. butyricum has been shown to have potential protective or ameliorating effects on a variety of human and animal diseases, including gut-acquired infections, irritable bowel syndrome, inflammatory bowel disease, neurodegenerative disease, metabolic disease, and colonic rectal cancer [ 23 , 32 ]. However, the effect of C. butyricum on endometritis has not been reported.…”

“…This indicated that C. butyricum and its culture supernatant had an antibacterial effect. The antibacterial effect of C. butyricum has been reported in several studies [ 32 , 36 ]. Our results once again proved the data of previous studies.…”

Intestinal Engineered Probiotics as Living Therapeutics: Chassis Selection, Colonization Enhancement, Gene Circuit Design, and Biocontainment

“…Moreover, probiotics including Bacteroides (e.g., Bacteroides fragilis ), Clostridium butyricum , and Saccharomyces boulardii are also being developed as the next generation of probiotic chassis. These probiotics possess good anti-infection properties, protect gut barrier function, − regulate host immunity, and promote anti-inflammatory effects. ,− Moreover, they exhibit novel features. For example, Bacteroidetes are powerful colonizers of colonic crypts, which are inaccessible to common probiotics. − C. butyricum has been used to treat antibiotic-associated diarrhea in many countries and can produce anti-inflammatory metabolites, such as butyrate and β-hydroxybutyrate, as well as spores to resist the harsh environment of the gut …”

Cancer-associated Lactobacillus iners are genetically distinct and associated with chemoradiation resistance in cervical cancer

“…For example, in the setting of bacterial vaginosis (BV), another disease defined by overgrowth of a particular vaginal microbe which competes with beneficial Lactobacilli, the application of topical metronidazole followed by a constitution of a beneficial strain of L. crispatus, known as LACTIN-V, resulted in the presence of L. crispatus in nearly 80% of patients 12 weeks after initial treatment with relatively few side effects and decreased the risk of BV recurrence by 1/3 (Cohen et al, 2020). Other potential focused interventions to eliminate L. iners such as topical application of specific bacteriocins, lytic phage use, or probiotics have successfully been used to treat recurrent clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA) infections (Nataraj and Mallappa, 2021;Ariyoshi et al, 2022).…”